ENGLEWOOD, NJ — July 16th, 2026 — When breast cancer is caught while it is still confined to the breast, the five-year relative survival rate is about 99%. Once it has spread to distant parts of the body, that figure falls to roughly 31%, according to the National Cancer Institute. SpotitEarly is working to move far more patients into that first group with a screening test as simple as breathing into a mask. Today, the multi-cancer early-detection company announced a strategic partnership with HITLAB (Healthcare Innovation and Technology Lab), a globally recognized health-technology research and innovation organization based in New York City, to accelerate its U.S. commercialization and capital development.

SpotitEarly’s platform does something no conventional screening test does: it reads the odor signature of cancer in a person’s breath. Its LUCID Bio-AI Hybrid system combines machine learning with the scent-detection abilities of trained canines, using sensors to capture and standardize the dogs’ behavioral and physiological responses into consistent, data-driven results. In the peer-reviewed, double-blind Rainbow Study, published in Scientific Reports, the platform achieved 93.9% sensitivity and 94.3% specificity.

Under the partnership, HITLAB will support SpotitEarly’s U.S. growth through investor introductions, strategic advisory, and speaking opportunities at its 2026 flagship events. HITLAB brings an established network of healthcare-focused investors and industry leaders, along with deep experience validating and commercializing health technologies—assets SpotitEarly can put to work as it advances multiple clinical studies with leading U.S. health systems and prepares to bring its breast cancer breath test to market in 2027.

“We’ve built the clinical evidence and the partnerships with world-class institutions,” said Shlomi Madar, PhD, CEO of SpotitEarly. “The next step is making sure the investment and healthcare communities see what our data shows and understand the scale of the opportunity. HITLAB sits at the center of digital health innovation and connects us directly with the investors, health-system leaders, and key opinion leaders who can help bring this technology to the patients who need it.”

Founded in 1998 and affiliated with Columbia University, HITLAB has worked with organizations including Pfizer, Johnson & Johnson, Eli Lilly, Novo Nordisk, Microsoft, and AWS. Its leadership team includes executives with backgrounds at Johnson & Johnson, Boehringer Ingelheim, and UnitedHealthcare/Optum.

“SpotitEarly represents the kind of evidence-backed, patient-centered innovation HITLAB was built to support,” said Stan Kachnowski, PhD, MPA, Chair of HITLAB. “Their published clinical data, combined with a genuinely novel approach to cancer detection, positions them to close one of the most significant gaps in preventive care. We look forward to connecting them with the investor and industry networks that can help take this technology to scale.”

SpotitEarly is advancing several clinical studies across the United States. The PINK Study, a 2,000-participant, multicenter breast cancer trial, is being conducted in partnership with Hackensack Meridian Health and the University of Pennsylvania, and the company is pursuing a lung cancer research collaboration with Fox Chase Cancer Center, part of Temple Health.

As the company looks to raise the next round of funding to continue advancing its mission, the team is also kicking off a national investment roadshow running from June 16-30th, starting in New York and stopping in other major cities, including Miami, Los Angeles, and Palo Alto. The tour will offer investors and family offices the opportunity to learn more about the company, its groundbreaking technology, and its product roadmap as it prepares to become commercially available in 2027.